However, most of the patients of our study population were treated with anti‐inflammatory drugs (Table 1), suggesting that reduction of ct‐CD45 levels in RA and SLE patients might be due to certain immunosuppressive therapies rather than a result of a common disease mechanism. This evidence concerns the gene PTPRC and rheumatoid arthritis.